We have just released the latest data update to the Open Targets Platform — 22.02.
Key highlights for this release:
- Gene2Phenotype has updated their terminology, in line with the terms established by the Gene Curation Coalition (GenCC). This is reflected in the Platform.
- We have integrated new data from several providers, in particular the OT Genetics portal and ChEMBL.
- The Open Targets COVID-19 target prioritisation tool has been deprecated, but the data is available in the Open Targets Platform.
This release integrates 10,880,832 evidence strings to build 7,980,448 target-disease associations between 18,468 diseases and 61,524 targets from the following 22 public resources:
- 1,112,480 genetic evidence from European Variation Archive (EVA)
- 693,583 genetic evidence from Open Targets Genetics Portal
- 3,159 genetic evidence from Gene2Phenotype
- 25,109 genetic evidence from the Genomics England PanelApp
- 1,574 genetic evidence from ClinGen
- 5,989 genetic evidence from Orphanet
- 171,390 genetic evidence from the PheWAS catalog
- 5,160 genetic evidence from UniProt Literature
- 11,547 somatic evidence from European Variation Archive (EVA)
- 3,299 somatic evidence from intOGen
- 74,159 somatic evidence from the Cancer Gene Census
- 33,906 somatic evidence from Uniprot
- 560,562 drug evidence from ChEMBL
- 231,165 expression evidence from Expression Atlas
- 9,943 affected pathway evidence from Reactome
- 72,370 affected pathway evidence from SLAPenrich
- 378 affected pathway evidence from PROGENy
- 389 systems biology evidence from SysBio
- 1,299 somatic evidence from the Cancer Genome Interpreter
- 1,828 CRISPR-Cas9 (Cancer Cell Lines) evidence from Behan et al. 2019
- 1,180,496 mouse model evidence from PhenoDigm
- 6,681,037 scientific literature evidence from co-occurence mining in Europe PMC
Additionally, the Platform now allows users to explore data on 12,594 drugs.
For more details, read the 22.02 release blog post.